- ICH GCP
- Rejestr badań klinicznych w USA
- Badanie kliniczne NCT07939529
People With Active Viremia Treated With Lenacapavir and Long-Acting Cabotegravir for Effectiveness (PALACE)
This pilot, single-arm, open-label study conducted in the United States will evaluate the efficacy, safety, tolerability, and pharmacokinetics of long-acting lenacapavir plus cabotegravir (LA LEN+CAB) in people with HIV-1 viremia who have a history of non-adherence and confirmed or suspected rilpivirine (RPV) resistance. Participants will be on study for up to 108 weeks.
Przegląd badań
Status
Warunki
Interwencja / Leczenie
Typ studiów
Zapisy (Szacowany)
Faza
- Faza 1
Kontakty i lokalizacje
Lokalizacje studiów
-
-
Alabama
-
Birmingham, Alabama, Stany Zjednoczone, 35222
- Alabama (Site ID: 31788)
-
Kontakt:
- Heather Logan
- Numer telefonu: 205-934-6774
- E-mail: heatherlogan@uabmc.edu
-
-
California
-
Los Angeles, California, Stany Zjednoczone, 90035
- University of California, Los Angeles CARE Center (Site ID: 601)
-
Kontakt:
- Aleen Khodabakhshian
- Numer telefonu: 310-557-3798
- E-mail: akhodabakhshian@mednet.ucla.edu
-
San Diego, California, Stany Zjednoczone, 92103
- UCSD Antiviral Research Center (Site ID: 701)
-
Kontakt:
- Dawn Rosenblum
- Numer telefonu: 619-543-8080
- E-mail: drosenblum@health.ucsd.edu
-
San Francisco, California, Stany Zjednoczone, 94110
- University of California, San Francisco (Site ID: 801)
-
Kontakt:
- Jay Dwyer
- Numer telefonu: 415-502-5748
- E-mail: jay.dwyer@ucsf.edu
-
Torrance, California, Stany Zjednoczone, 90502-2052
- Harbor University of California Los Angeles Center (Site ID: 603)
-
Kontakt:
- Mario Guerrero
- Numer telefonu: 323-457-1459
- E-mail: mguerrero@lundquist.org
-
-
Colorado
-
Aurora, Colorado, Stany Zjednoczone, 80045
- University of Colorado Hospital (Site ID: 6101)
-
Kontakt:
- Nicola Haakonsen
- Numer telefonu: 303-724-5931
- E-mail: nicola.haakonsen@cuanschutz.edu
-
-
District of Columbia
-
Washington D.C., District of Columbia, Stany Zjednoczone, 20032
- Whitman-Walker Institute, Inc. (Site ID: 21791)
-
Kontakt:
- Avery Wimpelberg
- Numer telefonu: 202-797-3589
- E-mail: awimpelberg@whitman-walker.org
-
-
Illinois
-
Chicago, Illinois, Stany Zjednoczone, 60611
- Northwestern University (Site ID: 2701)
-
Kontakt:
- Sherryl L Wolfe
- Numer telefonu: 312-695-4997
- E-mail: s-wolfe@northwestern.edu
-
-
Maryland
-
Baltimore, Maryland, Stany Zjednoczone, 21287
- Johns Hopkins University (Site ID: 201)
-
Kontakt:
- Rebecca L Becker
- Numer telefonu: 410-614-4036
- E-mail: rbecke22@jhmi.edu
-
-
Massachusetts
-
Boston, Massachusetts, Stany Zjednoczone, 02114
- Massachusetts General Hospital (Site ID: 101)
-
Kontakt:
- Amy Sbrolla
- Numer telefonu: 617-726-5598
- E-mail: asbrolla@mgh.harvard.edu
-
Boston, Massachusetts, Stany Zjednoczone, 02115
- Brigham and Women's Hospital Therapeutics (BWH TCRS) (Site ID: 107)
-
Kontakt:
- Hannah Jordan
- Numer telefonu: 617-732-4785
- E-mail: hcjordan@bwh.harvard.edu
-
-
New Jersey
-
Newark, New Jersey, Stany Zjednoczone, 07103
- New Jersey Medical School Clinical Research Center (Site ID: 31786)
-
Kontakt:
- Christie Lyn Costanza
- Numer telefonu: 972-972-9069
- E-mail: costancl@njms.rutgers.edu
-
-
New York
-
New York, New York, Stany Zjednoczone, 10010
- Weill Cornell Chelsea (Site ID: 7804)
-
Kontakt:
- Mauricio Vergara
- Numer telefonu: 212-746-7204
- E-mail: mav9177@med.cornell.edu
-
New York, New York, Stany Zjednoczone, 10010
- Weill Cornell Uptown (Site ID: 7803)
-
Kontakt:
- Keisha Ballentine-Cargill
- Numer telefonu: 212-746-7804
- E-mail: keb4006@med.cornell.edu
-
New York, New York, Stany Zjednoczone, 10032
- Columbia Physicians & Surgeons (P&S) (Site ID: 30329)
-
Kontakt:
- Brett T Gray
- Numer telefonu: 212-305-1570
- E-mail: bg2168@cumc.columbia.edu
-
-
North Carolina
-
Chapel Hill, North Carolina, Stany Zjednoczone, 27599-7215
- Chapel Hill (Site ID: 3201)
-
Kontakt:
- Erin Elizabeth Hoffman
- Numer telefonu: 919-843-0720
- E-mail: erin_hoffman@med.unc.edu
-
Greensboro, North Carolina, Stany Zjednoczone, 27401-1020
- Greensboro (Site ID: 3203)
-
Kontakt:
- Kelly Phillips
- Numer telefonu: 336-832-7297
- E-mail: kelly.phillips@conehealth.com
-
-
Ohio
-
Cincinnati, Ohio, Stany Zjednoczone, 45267-0405
- Cincinnati Clinical Research Site (Site ID: 2401)
-
Kontakt:
- Michelle Saemann
- Numer telefonu: 513-584-2245
- E-mail: saemanmd@ucmail.uc.edu
-
Cleveland, Ohio, Stany Zjednoczone, 44106
- Case Clinical Research Site (Site ID: 2501)
-
Kontakt:
- Julie Pasternak
- Numer telefonu: 216-844-2738
- E-mail: pasternak.julie@clevelandactu.org
-
Columbus, Ohio, Stany Zjednoczone, 43210
- Ohio State University (Site ID: 2301)
-
Kontakt:
- Lindsay Summers
- Numer telefonu: 614-293-8529
- E-mail: lindsay.summers@osumc.edu
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, Stany Zjednoczone, 15213
- University of Pittsburgh (Site ID: 1001)
-
Kontakt:
- Stacey Edick
- Numer telefonu: 412-383-1748
- E-mail: edicksm2@upmc.edu
-
-
Tennessee
-
Nashville, Tennessee, Stany Zjednoczone, 37204
- Vanderbilt Therapeutics (VT) (Site ID: 3652)
-
Kontakt:
- Beverly Woodward
- Numer telefonu: 615-936-8516
- E-mail: beverly.o.woodward@vumc.org
-
-
Texas
-
Houston, Texas, Stany Zjednoczone, 77030
- Houston Advancing Research Team (Site ID: 31473)
-
Kontakt:
- Maria Laura Martinez
- Numer telefonu: 713-500-6718
- E-mail: maria.l.martinez@uth.tmc.edu
-
-
Washington
-
Seattle, Washington, Stany Zjednoczone, 98104
- University of Washington Positive Research (Site ID: 1401)
-
Kontakt:
- Allysson Angeldekao
- Numer telefonu: 503-715-7324
- E-mail: allysson@uw.edu
-
-
Kryteria uczestnictwa
Kryteria kwalifikacji
Wiek uprawniający do nauki
Akceptuje zdrowych ochotników
Płeć kwalifikująca się do nauki
Opis
Inclusion Criteria:
-
Documented HIV-1 infection
-
Prior antiretroviral therapy (ART) experience, including having first been prescribed ART at least 24 weeks prior to enrollment and self-report of prior oral ART use
-
HIV-1 RNA >1000 copies/mL within 60 days prior to study entry
-
Evidence of non-adherence to ART, including virologic failure, poor virologic response, or loss to clinical follow-up with ART non-use/non-adherence
-
At least one reason why NNRTI-based ART is clinically inappropriate, including documented or suspected rilpivirine resistance or prior rilpivirine intolerance
-
Adequate laboratory parameters within 60 days prior to study entry:
- Absolute neutrophil count >600/mm3
- Hemoglobin ≥7.0 g/dL
- Platelet count >50,000/μL
- AST and ALT ≤3 × upper limit of normal
- Estimated glomerular filtration rate >15 mL/min/1.73 m²
-
For participants of childbearing potential, negative pregnancy test at screening and within 24 hours prior to study entry
-
Ability and willingness to provide informed consent
-
Connected to a medical clinic with access to HIV care and antiretroviral therapy
Exclusion Criteria:
- Documented integrase strand transfer inhibitor (INSTI) resistance-associated mutations that may compromise cabotegravir activity
- Active hepatitis B infection, defined as positive hepatitis B surface antigen or detectable hepatitis B virus DNA
- Child-Pugh Class C cirrhosis
- No suitable injection site for cabotegravir administration due to implants, tattoos, or skin conditions interfering with injection site assessment
- Prior use of lenacapavir
- Receipt of HIV immunotherapeutic vaccines or HIV monoclonal antibodies within 6 months prior to study entry
- Serious medical or psychiatric condition
- Use of prohibited concomitant medications with lenacapavir or cabotegravir within 30 days prior to study entry
- Current pregnancy or breastfeeding
- Known allergy, hypersensitivity, or intolerance to cabotegravir, lenacapavir, or formulation components
Plan studiów
Jak projektuje się badanie?
Szczegóły projektu
- Główny cel: Leczenie
- Przydział: Nie dotyczy
- Model interwencyjny: Zadanie dla jednej grupy
- Maskowanie: Brak (otwarta etykieta)
Broń i interwencje
Grupa uczestników / Arm |
Interwencja / Leczenie |
|---|---|
|
Eksperymentalny: Long-Acting Lenacapavir Plus Long-Acting Cabotegravir
|
Long-acting subcutaneous lenacapavir administered every 24 weeks with oral loading doses at treatment initiation. Long-acting intramuscular cabotegravir administered every 8 weeks following initiation doses. Oral antiretroviral therapy provided as bridge therapy during interruptions or delays in long-acting treatment. |
Co mierzy badanie?
Podstawowe miary wyniku
Miara wyniku |
Ramy czasowe |
|---|---|
|
Proportion of participants achieving and maintaining viral suppression (no confirmed virologic failure) while receiving long-acting lenacapavir plus cabotegravir
Ramy czasowe: Baseline through Week 48
|
Baseline through Week 48
|
Miary wyników drugorzędnych
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Proportion of participants with HIV-1 RNA <50 copies/mL by FDA Snapshot analysis
Ramy czasowe: Week 48
|
Week 48
|
|
|
Proportion of participants with HIV-1 RNA <200 copies/mL by FDA Snapshot analysis
Ramy czasowe: Week 48
|
Week 48
|
|
|
Proportion of participants with regimen success, defined as remaining on long-acting lenacapavir plus cabotegravir without confirmed virologic failure
Ramy czasowe: Week 48
|
Week 48
|
|
|
Proportion of participants with Grade 3 or higher adverse events related to long-acting lenacapavir plus cabotegravir
Ramy czasowe: Baseline through Week 96
|
Baseline through Week 96
|
|
|
Proportion of participants discontinuing long-acting lenacapavir plus cabotegravir due to adverse events or intolerance
Ramy czasowe: Baseline through Week 96
|
Baseline through Week 96
|
|
|
Proportion of participants achieving and maintaining viral suppression without confirmed virologic failure on long-acting lenacapavir plus cabotegravir
Ramy czasowe: Baseline through Week 96
|
Baseline through Week 96
|
|
|
Proportion of participants with HIV-1 RNA <50 copies/mL by FDA Snapshot analysis
Ramy czasowe: Week 96
|
Week 96
|
|
|
Proportion of participants with HIV-1 RNA <200 copies/mL by FDA Snapshot analysis
Ramy czasowe: Week 96
|
Week 96
|
|
|
Proportion of participants with regimen success, defined as remaining on long-acting lenacapavir plus cabotegravir without confirmed virologic failure
Ramy czasowe: Week 96
|
Week 96
|
|
|
Percentage of on-time long-acting injections
Ramy czasowe: Through Week 48 and through Week 96
|
Through Week 48 and through Week 96
|
|
|
Proportion of participants discontinuing long-acting lenacapavir plus cabotegravir
Ramy czasowe: Baseline through Week 48 and through Week 96
|
Baseline through Week 48 and through Week 96
|
|
|
Plasma trough concentrations of lenacapavir and cabotegravir
Ramy czasowe: Through Week 48 and through Week 96
|
Through Week 48 and through Week 96
|
|
|
Change in CD4 cell count from baseline
Ramy czasowe: Week 48 and Week 96
|
Week 48 and Week 96
|
|
|
Participant-reported treatment satisfaction
Ramy czasowe: Week 48 and Week 96
|
HIV Treatment Satisfaction Questionnaire assesses participant satisfaction with the long-acting treatment. |
Week 48 and Week 96
|
|
Change in quality-of-life scores from baseline
Ramy czasowe: Week 48 and Week 96
|
Quality of life will be assessed using the Veterans Rand 12-item Health Survey (VR-12). Scores range from 0 to 100, with higher scores indicating better health-related quality of life. |
Week 48 and Week 96
|
|
Change in Patient Health Questionnaire-9 (PHQ-9) scores from baseline
Ramy czasowe: Week 48 and Week 96
|
Symptoms will be assessed using the Patient Health Questionnaire-9 (PHQ-9). Scores range from 0 to 27, with higher scores indicating more severe depressive symptoms. |
Week 48 and Week 96
|
|
Proportion of participants achieving and maintaining viral suppression without confirmed virologic failure among participants not requiring oral bridge therapy
Ramy czasowe: Baseline through Week 48
|
Baseline through Week 48
|
|
|
Proportion of participants without oral bridge therapy with HIV-1 RNA <50 copies/mL by FDA Snapshot analysis
Ramy czasowe: Week 48
|
Week 48
|
|
|
Proportion of participants without oral bridge therapy with HIV-1 RNA <200 copies/mL by FDA Snapshot analysis
Ramy czasowe: Week 48
|
Week 48
|
|
|
Proportion of participants without oral bridge therapy with regimen success, defined as remaining on long-acting lenacapavir plus cabotegravir without confirmed virologic failure
Ramy czasowe: Week 48
|
Week 48
|
Współpracownicy i badacze
Daty zapisu na studia
Główne daty studiów
Rozpoczęcie studiów (Szacowany)
Zakończenie podstawowe (Szacowany)
Ukończenie studiów (Szacowany)
Daty rejestracji na studia
Pierwszy przesłany
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy wysłany (Rzeczywisty)
Aktualizacje rekordów badań
Ostatnia wysłana aktualizacja (Rzeczywisty)
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia weryfikacja
Więcej informacji
Terminy związane z tym badaniem
Słowa kluczowe
Dodatkowe istotne warunki MeSH
Inne numery identyfikacyjne badania
- A5431
- 39159 (Inny identyfikator: DAIDS-ES ID)
Plan dla danych uczestnika indywidualnego (IPD)
Planujesz udostępniać dane poszczególnych uczestników (IPD)?
Opis planu IPD
Individual participant data that underlie results in the publication after deidentification
Ramy czasowe udostępniania IPD
Beginning 3 months following publication and available throughout period of funding of the Advancing Clinical Therapeutics Globally (ACTG) by NIH
Kryteria dostępu do udostępniania IPD
With whom? Researchers who provide a methodologically sound proposal for use of the data that is approved by the ACTG.
For what types of analyses? To achieve aims in the proposal approved by the ACTG.
By what mechanism will data be made available? Researchers may submit a request for access to data using the ACTG "Data Request" form at: https://actgnetwork.org/submit-a-proposal/. Researchers of approved proposals will need to sign an ACTG Data Use Agreement before receiving the data
Typ informacji pomocniczych dotyczących udostępniania IPD
- PROTOKÓŁ BADANIA
- SOK ROŚLINNY
Informacje o lekach i urządzeniach, dokumenty badawcze
Bada produkt leczniczy regulowany przez amerykańską FDA
Bada produkt urządzenia regulowany przez amerykańską FDA
Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .